TNGX - Company ID 0001819133
The table below shows Tango Therapeutics, Inc.'s cash flow statement by quarter, as reported in the company's quarterly filings. All figures are in US dollars; negative values appear in red.
| Line item | Q1 2026 | Q1 2025 | Q1 2024 | Q1 2023 | Q1 2022 | Q1 2021 |
|---|---|---|---|---|---|---|
| Operating cash flow | -$44.36M | -$41.70M | -$37.86M | -$34.91M | -$29.66M | -$13.61M |
| Capital expenditure | -$2.00K | $51.00K | $195.00K | $620.00K | $1.56M | $165.00K |
| Investing cash flow | $9.63M | $30.60M | -$11.20M | $31.55M | -$11.72M | $20.61M |
| Dividends paid | - | - | - |
Tango Therapeutics, Inc. reported operating cash flow of -$138.89M for fiscal year 2025. That is down 5.6% from -$131.50M in fiscal 2024. Over the 6 fiscal years shown, operating cash flow declined from $70.07M (FY 2020) to -$138.89M. Figures come from the company's audited annual reports as filed with the SEC.
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
| - |
| - |
| - |
| Stock buybacks | - | - | - | - | - | - |
| Financing cash flow | $79.85M | $2.00K | $42.98M | $73.00K | $257.00K | $30.41M |